ICH – Page 2 – DSI InPharmatics

April 1, 2021

Published by Meranda Parascandola at April 1, 2021

Establishing Regulatory Starting Materials & Understanding the ICH

There are many ways for companies to get approvals for expedited development. This is primarily based on trials and data from clinical studies. The biggest issue has always been how acceleration impacts CMC. In many cases, the data and the programs need time and cannot be expedited. So how do you ensure CMC doesn't become the bottleneck?

September 18, 2023

Published by Meranda Parascandola at September 18, 2023

What is a Quality Management System?

A robust Quality Management System (QMS) is an important aspect of a Pharmaceutical company as it demonstrates a company’s Senior Management commitment to Quality. QMS instills the mindset that assures that the company will have qualified and trained individuals who focus on “Quality” throughout the lifecycle of the product.

September 25, 2023

Published by Meranda Parascandola at September 25, 2023

DECENTRALIZED CLINICAL TRIALS FOR DRUGS, BIOLOGICAL PRODUCTS, AND DEVICES

Usually, activities in clinical trials are conducted in clinical trial sites that are experienced or well-versed in clinical trials. In fully decentralized clinical trials (DCTs), all activities occur at locations other than traditional trial sites, such as at the homes of trial participants or in local healthcare facilities that are convenient for trial participants